| scholarly article | Q13442814 |
| P356 | DOI | 10.1158/0008-5472.CAN-06-0190 |
| P698 | PubMed publication ID | 16818641 |
| P50 | author | Kenneth C. Anderson | Q28421846 |
| Weihua Song | Q39949167 | ||
| Paul G. Richardson | Q87712102 | ||
| Nikhil V Munshi | Q89228014 | ||
| Klaus Podar | Q92660028 | ||
| Iris Breitkreutz | Q96098386 | ||
| Robert Schlossman | Q114300414 | ||
| Noopur Raje | Q114442101 | ||
| Teru Hideshima | Q114455520 | ||
| Dharminder Chauhan | Q117224711 | ||
| Laurence P Catley | Q117224725 | ||
| P2093 | author name string | Yu-Tzu Tai | |
| Paola Neri | |||
| Xian-Feng Li | |||
| P433 | issue | 13 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | multiple myeloma | Q467635 |
| P304 | page(s) | 6675-6682 | |
| P577 | publication date | 2006-07-01 | |
| P1433 | published in | Cancer Research | Q326097 |
| P1476 | title | Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment | |
| P478 | volume | 66 |
| Q37035836 | APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment. |
| Q56889868 | APRIL signaling via TACI mediates immunosuppression by T regulatory cells in multiple myeloma: therapeutic implications |
| Q28743862 | Aberrant expression of functional BAFF-system receptors by malignant B-cell precursors impacts leukemia cell survival |
| Q37397839 | Abnormal cytokine production by bone marrow stromal cells of multiple myeloma patients in response to RPMI8226 myeloma cells. |
| Q48334966 | An APRIL based chimeric antigen receptor for dual targeting of BCMA and TACI in Multiple Myeloma. |
| Q36835070 | Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu |
| Q35431150 | Antibody-based therapies in multiple myeloma |
| Q37407676 | Atacicept (TACI-Ig) inhibits growth of TACI(high) primary myeloma cells in SCID-hu mice and in coculture with osteoclasts |
| Q37400568 | Atacicept in relapsed/refractory multiple myeloma or active Waldenström's macroglobulinemia: a phase I study |
| Q50889230 | Autoantibodies in patients with monoclonal gammopathies. |
| Q36670808 | B cell activating factor in obesity is regulated by oxidative stress in adipocytes |
| Q38365867 | B-cell activating factor in the pathophysiology of multiple myeloma: a target for therapy? |
| Q36778126 | B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma |
| Q36990979 | B-cell maturation antigen is modified by a single N-glycan chain that modulates ligand binding and surface retention |
| Q37622417 | BAFF and APRIL as TNF superfamily molecules and angiogenesis parallel progression of human multiple myeloma. |
| Q47669883 | BAFF is involved in macrophage-induced bortezomib resistance in myeloma. |
| Q36111799 | Bioinformatics analyses of differentially expressed genes associated with bisphosphonate-related osteonecrosis of the jaw in patients with multiple myeloma |
| Q37201984 | Biologic sequelae of I{kappa}B kinase (IKK) inhibition in multiple myeloma: therapeutic implications |
| Q50888455 | Bone Disease in Multiple Myeloma. |
| Q50182712 | Bone Marrow Stroma and Vascular Contributions to Myeloma Bone Homing. |
| Q34045789 | Bone disease in multiple myeloma: pathophysiology and management. |
| Q36162703 | Bone marrow microenvironment and the identification of new targets for myeloma therapy |
| Q34155848 | Bone marrow microenvironment in myelomagenesis: its potential role in early diagnosis |
| Q55395268 | Bone-targeted agents in multiple myeloma. |
| Q37291635 | Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells |
| Q36206430 | Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma |
| Q98771206 | CAR T-Cells in Multiple Myeloma: State of the Art and Future Directions |
| Q33749646 | CD28-mediated pro-survival signaling induces chemotherapeutic resistance in multiple myeloma |
| Q37445828 | CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications. |
| Q37176556 | CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cells |
| Q38062038 | Can we change the disease biology of multiple myeloma? |
| Q36925346 | Cellular mechanisms of multiple myeloma bone disease |
| Q33839840 | Classical and/or alternative NF-kappaB pathway activation in multiple myeloma |
| Q58582611 | Clinical impact of serum soluble SLAMF7 in multiple myeloma |
| Q28727049 | Defining an EPOR- regulated transcriptome for primary progenitors, including Tnfr-sf13c as a novel mediator of EPO- dependent erythroblast formation |
| Q28066890 | Development of Novel Immunotherapies for Multiple Myeloma |
| Q33433447 | Dose-escalation study of tabalumab with bortezomib and dexamethasone in Japanese patients with multiple myeloma |
| Q39643606 | Downregulation of B lymphocyte stimulator expression by curcumin in B lymphocyte via suppressing nuclear translocation of NF-κB |
| Q42224441 | Enhancement of myeloma development mediated though myeloma cell-Th2 cell interactions after microbial antigen presentation by myeloma cells and DCs |
| Q38095958 | Experimental approaches in the treatment of multiple myeloma |
| Q38101284 | FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance |
| Q34650781 | Frequent engagement of RelB activation is critical for cell survival in multiple myeloma |
| Q27314650 | Fusion toxin BLyS-gelonin inhibits growth of malignant human B cell lines in vitro and in vivo |
| Q37924891 | Genetic variations in multiple myeloma I: effect on risk of multiple myeloma |
| Q27001749 | Heparan sulfate proteoglycans in the control of B cell development and the pathogenesis of multiple myeloma |
| Q37724368 | Humoral immunotherapy of multiple myeloma: perspectives and perplexities. |
| Q47945565 | Interleukin-10 and interferon-gamma up-regulate the expression of B-cell activating factor in cultured human promyelocytic leukemia cells |
| Q46505738 | Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma |
| Q39931092 | Lymphoma cell adhesion-induced expression of B cell-activating factor of the TNF family in bone marrow stromal cells protects non-Hodgkin's B lymphoma cells from apoptosis |
| Q26765477 | MicroRNAs: Novel Crossroads between Myeloma Cells and the Bone Marrow Microenvironment |
| Q92212407 | Microbial antigens-loaded myeloma cells enhance Th2 cell proliferation and myeloma clonogenicity via Th2-myeloma cell interaction |
| Q39945195 | Molecular targeting of the PKC-beta inhibitor enzastaurin (LY317615) in multiple myeloma involves a coordinated downregulation of MYC and IRF4 expression |
| Q60909519 | Monoclonal Antibodies for the Treatment of Multiple Myeloma: An Update |
| Q49539698 | Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets |
| Q90241569 | Monoclonal Antibody: A New Treatment Strategy against Multiple Myeloma |
| Q99604845 | Monoclonal and Bispecific Anti-BCMA Antibodies in Multiple Myeloma |
| Q38205856 | Monoclonal antibodies currently in Phase II and III trials for multiple myeloma. |
| Q38090691 | Monoclonal antibodies: potential new therapeutic treatment against multiple myeloma |
| Q38956372 | Monoclonal antibody therapy in multiple myeloma. |
| Q37919717 | Monoclonal antibody-based therapy as a new treatment strategy in multiple myeloma |
| Q36522964 | Multiple Myeloma: Treatment is Getting Individualized |
| Q37815266 | Multiple myeloma: biology of the disease |
| Q38598342 | Myeloma and Bone Disease |
| Q39137696 | New monoclonal antibodies on the horizon in multiple myeloma |
| Q33958520 | New strategies in the treatment of multiple myeloma |
| Q36673755 | Novel Bruton's tyrosine kinase inhibitors currently in development |
| Q33621610 | Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. |
| Q37707383 | Novel therapeutic targets for multiple myeloma |
| Q34025065 | Novel therapeutic targets in myeloma bone disease |
| Q34778972 | Novel tumor suppressor function of glucocorticoid-induced TNF receptor GITR in multiple myeloma |
| Q58790080 | Osteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1 |
| Q37737793 | PI3Kδ and PI3Kγ isoforms have distinct functions in regulating pro-tumoural signalling in the multiple myeloma microenvironment |
| Q33437811 | Phase 2 study of tabalumab, a human anti-B-cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma. |
| Q97423201 | Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T cells for treatment of multiple myeloma |
| Q36998210 | Preclinical studies of novel targeted therapies |
| Q39322974 | Role of interleukin 16 in multiple myeloma |
| Q39051838 | Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients |
| Q59245070 | Single nucleotide polymorphisms in the promoter region of the IL1B gene influence outcome in multiple myeloma patients treated with high-dose chemotherapy independently of relapse treatment with thalidomide and bortezomib |
| Q38810089 | Study on the Association Between miRNA-202 Expression and Drug Sensitivity in Multiple Myeloma Cells |
| Q36462782 | Surface-tension driven open microfluidic platform for hanging droplet culture |
| Q42960413 | TACI expression is associated with a mature bone marrow plasma cell signature and C-MAF overexpression in human myeloma cell lines. |
| Q58790069 | Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy |
| Q38586922 | Targeting B-cell maturation antigen in multiple myeloma |
| Q35989478 | Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis |
| Q35603128 | Targeting bone as a therapy for myeloma. |
| Q38970585 | Targeting the Bone Marrow Microenvironment. |
| Q37946702 | Targeting the interplay between myeloma cells and the bone marrow microenvironment in myeloma |
| Q55657825 | The NF-κB Activating Pathways in Multiple Myeloma. |
| Q89604473 | The clinical potential of gene editing as a tool to engineer cell-based therapeutics |
| Q37718836 | The genetic architecture of multiple myeloma |
| Q28538422 | Toll-like receptor (TLR)-1/2 triggering of multiple myeloma cells modulates their adhesion to bone marrow stromal cells and enhances bortezomib-induced apoptosis |
| Q38472064 | Toll-like receptor 4-mediated cAMP production up-regulates B-cell activating factor expression in Raw264.7 macrophages |
| Q39409852 | Triptolide enhances the sensitivity of multiple myeloma cells to dexamethasone via microRNAs |
| Q38065305 | Understanding the molecular biology of myeloma and its therapeutic implications |
| Q50558366 | Unlike αβ T cells, γδ T cells, LTi cells and NKT cells do not require IRF4 for the production of IL-17A and IL-22. |
| Q50999969 | [miR-202 contributes to sensitizing MM cells to drug significantly via activing JNK/SAPK signaling pathway]. |
| Q53508723 | miRNA-202 in bone marrow stromal cells affects the growth and adhesion of multiple myeloma cells by regulating B cell-activating factor. |
Search more.